Download PDF
Hamostaseologie 2020; 40(02): 145-152
DOI: 10.1055/a-1113-0711
Review Article
Georg Thieme Verlag KG Stuttgart · New York

Platelet Purinergic Receptors in Thrombosis and Inflammation

Christian Gachet
1   Etablissement Français du Sang (EFS) Grand Est, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg Cedex, France
,
Beatrice Hechler
1   Etablissement Français du Sang (EFS) Grand Est, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg Cedex, France
› Author Affiliations
Further Information

Publication History

12 November 2019

23 January 2020

Publication Date:
28 May 2020 (online)

Also available at
   Permissions and Reprints

Abstract

It took approximately 40 years from the seminal identification of adenosine diphosphate (ADP) as the factor R, an agent derived from red blood cells inducing platelet adhesion to glass, to the completion of the repertoire of its receptors on platelets and its importance in haemostasis and thrombosis. ADP, either derived from red blood cells or released by platelets themselves, stimulates platelets via two G protein-coupled receptors, P2Y1 and P2Y12. In addition, adenosine triphosphate, also contained in the platelet dense granules, activates the P2X1 cation channel. Each of these receptors plays a specific role during platelet activation and aggregation, with relevance to haemostasis, thrombosis and various inflammatory processes where platelets are involved including chronic responses such as atherosclerosis or acute responses such as sepsis, endotoxaemia or allergic asthma. Finally, platelets also express P2Y14, a receptor activated by released uridine diphosphate glucose. Although devoid of any known role in haemostasis, this receptor seems to play a specific role in neutrophil chemotaxis.

Keywords

nucleotides - platelets - thrombosis - inflammation - atherosclerosis

Disclosures

None.


 

  • References

  • 1 Gaarder A, Jonsen J, Laland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
    CrossrefPubMedGoogle Scholar
  • 2 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
    PubMedGoogle Scholar
  • 3 Maffrand JP, Bernat A, Delebassée D, Defreyn G, Cazenave JP, Gordon JL. ADP plays a key role in thrombogenesis in rats. Thromb Haemost 1988; 59 (02) 225-230
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Cattaneo M, Canciani MT, Lecchi A. , et al. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990; 75 (05) 1081-1086
    CrossrefPubMedGoogle Scholar
  • 5 Dovlatova N, Wijeyeratne YD, Fox SC. , et al. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. Thromb Haemost 2008; 100 (02) 261-270
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Hechler B, Léon C, Vial C. , et al. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998; 92 (01) 152-159
    CrossrefPubMedGoogle Scholar
  • 7 Léon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403 (01) 26-30
    CrossrefPubMedGoogle Scholar
  • 8 Waldo GL, Harden TK. Agonist binding and Gq-stimulating activities of the purified human P2Y1 receptor. Mol Pharmacol 2004; 65 (02) 426-436
    CrossrefPubMedGoogle Scholar
  • 9 Crittenden JR, Bergmeier W, Zhang Y. , et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004; 10 (09) 982-986
    CrossrefPubMedGoogle Scholar
  • 10 Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277-300
    CrossrefPubMedGoogle Scholar
  • 11 Hollopeter G, Jantzen HM, Vincent D. , et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409 (6817): 202-207
    CrossrefPubMedGoogle Scholar
  • 12 Zhang FL, Luo L, Gustafson E. , et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 2001; 276 (11) 8608-8615
    CrossrefPubMedGoogle Scholar
  • 13 Hechler B, Eckly A, Ohlmann P, Cazenave JP, Gachet C. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol 1998; 103 (03) 858-866
    CrossrefPubMedGoogle Scholar
  • 14 Trumel C, Payrastre B, Plantavid M. , et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94 (12) 4156-4165
    CrossrefPubMedGoogle Scholar
  • 15 Kauffenstein G, Hechler B, Cazenave JP, Gachet C. Adenine triphosphate nucleotides are antagonists at the P2Y receptor. J Thromb Haemost 2004; 2 (11) 1980-1988
    CrossrefPubMedGoogle Scholar
  • 16 Cattaneo M. The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011; 117 (07) 2102-2112
    CrossrefPubMedGoogle Scholar
  • 17 Gremmel T, Michelson AD, Frelinger III AL, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018; 2 (03) 439-449
    CrossrefPubMedGoogle Scholar
  • 18 Gachet C. P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal 2012; 8 (03) 609-619
    CrossrefPubMedGoogle Scholar
  • 19 Hechler B, Gachet C. Purinergic receptors in thrombosis and inflammation. Arterioscler Thromb Vasc Biol 2015; 35 (11) 2307-2315
    CrossrefPubMedGoogle Scholar
  • 20 Hao Y, Wang L, Chen H. , et al. Targetable purinergic receptors P2Y12 and A2b antagonistically regulate bladder function. JCI Insight 2019; 4 (16) 122112
    CrossrefPubMedGoogle Scholar
  • 21 Gratacap MP, Guillermet-Guibert J, Martin V. , et al. Regulation and roles of PI3Kβ, a major actor in platelet signaling and functions. Adv Enzyme Regul 2011; 51 (01) 106-116
    CrossrefPubMedGoogle Scholar
  • 22 Stefanini L, Paul DS, Robledo RF. , et al. RASA3 is a critical inhibitor of RAP1-dependent platelet activation. J Clin Invest 2015; 125 (04) 1419-1432
    CrossrefPubMedGoogle Scholar
  • 23 Lecchi A, Femia EA, Paoletta S. , et al. Inherited dysfunctional platelet P2Y12 receptor mutations associated with bleeding disorders. Hamostaseologie 2016; 36 (04) 279-283
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Hechler B, Lenain N, Marchese P. , et al. A role of the fast ATP-gated P2 × 1 cation channel in thrombosis of small arteries in vivo. J Exp Med 2003; 198 (04) 661-667
    CrossrefPubMedGoogle Scholar
  • 25 Cattaneo M. The P2 receptors and congenital platelet function defects. Semin Thromb Hemost 2005; 31 (02) 168-173
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Oury C, Toth-Zsamboki E, Van Geet C. , et al. A natural dominant negative P2 × 1 receptor due to deletion of a single amino acid residue. J Biol Chem 2000; 275 (30) 22611-22614
    CrossrefPubMedGoogle Scholar
  • 27 Gachet C. Antiplatelet drugs: which targets for which treatments?. J Thromb Haemost 2015; 13 (Suppl. 01) S313-S322
    CrossrefPubMedGoogle Scholar
  • 28 Zhang J, Zhang K, Gao ZG. , et al. Agonist-bound structure of the human P2Y12 receptor. Nature 2014; 509 (7498): 119-122
    PubMedGoogle Scholar
  • 29 Zhang K, Zhang J, Gao ZG. , et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature 2014; 509 (7498): 115-118
    PubMedGoogle Scholar
  • 30 Fabre JE, Nguyen M, Latour A. , et al. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5 (10) 1199-1202
    CrossrefPubMedGoogle Scholar
  • 31 Léon C, Hechler B, Freund M. , et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest 1999; 104 (12) 1731-1737
    CrossrefPubMedGoogle Scholar
  • 32 Léon C, Freund M, Ravanat C, Baurand A, Cazenave JP, Gachet C. Key role of the P2Y(1) receptor in tissue factor-induced thrombin-dependent acute thromboembolism: studies in P2Y(1)-knockout mice and mice treated with a P2Y(1) antagonist. Circulation 2001; 103 (05) 718-723
    CrossrefPubMedGoogle Scholar
  • 33 Lenain N, Freund M, Léon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J Thromb Haemost 2003; 1 (06) 1144-1149
    CrossrefPubMedGoogle Scholar
  • 34 Hechler B, Nonne C, Roh EJ. , et al. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Ther 2006; 316 (02) 556-563
    CrossrefPubMedGoogle Scholar
  • 35 Zhang D, Gao ZG, Zhang K. , et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature 2015; 520 (7547): 317-321
    PubMedGoogle Scholar
  • 36 Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as immune and inflammatory cells. Blood 2014; 123 (18) 2759-2767
    CrossrefPubMedGoogle Scholar
  • 37 Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature 2014; 509 (7500): 310-317
    PubMedGoogle Scholar
  • 38 Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Lüscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med 2007; 12 (02) 113-122
    CrossrefPubMedGoogle Scholar
  • 39 Evans DJ, Jackman LE, Chamberlain J. , et al. Platelet P2Y(12) receptor influences the vessel wall response to arterial injury and thrombosis. Circulation 2009; 119 (01) 116-122
    CrossrefPubMedGoogle Scholar
  • 40 Li D, Wang Y, Zhang L. , et al. Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2012; 32 (08) e81-e89
    PubMedGoogle Scholar
  • 41 West LE, Steiner T, Judge HM, Francis SE, Storey RF. Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res 2014; 102 (03) 429-435
    CrossrefPubMedGoogle Scholar
  • 42 Abele S, Spriewald BM, Ramsperger-Gleixner M. , et al. Attenuation of transplant arteriosclerosis with clopidogrel is associated with a reduction of infiltrating dendritic cells and macrophages in murine aortic allografts. Transplantation 2009; 87 (02) 207-216
    CrossrefPubMedGoogle Scholar
  • 43 Harada K, Matsumoto Y, Umemura K. Adenosine diphosphate receptor P2Y12-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis. Transplantation 2011; 92 (02) 148-154
    CrossrefPubMedGoogle Scholar
  • 44 Paruchuri S, Tashimo H, Feng C. , et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med 2009; 206 (11) 2543-2555
    CrossrefPubMedGoogle Scholar
  • 45 Cattaneo M. The platelet P2 receptors in inflammation. Hamostaseologie 2015; 35 (03) 262-266
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Amison RT, Momi S, Morris A. , et al. RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice. J Allergy Clin Immunol 2015; 135 (02) 528-538
    CrossrefPubMedGoogle Scholar
  • 47 Hagiwara S, Iwasaka H, Hasegawa A. , et al. Adenosine diphosphate receptor antagonist clopidogrel sulfate attenuates LPS-induced systemic inflammation in a rat model. Shock 2011; 35 (03) 289-292
    CrossrefPubMedGoogle Scholar
  • 48 Liverani E, Rico MC, Tsygankov AY, Kilpatrick LE, Kunapuli SP. P2Y12 receptor modulates sepsis-induced inflammation. Arterioscler Thromb Vasc Biol 2016; 36 (05) 961-971
    CrossrefPubMedGoogle Scholar
  • 49 Léon C, Ravanat C, Freund M, Cazenave JP, Gachet C. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol 2003; 23 (10) 1941-1947
    CrossrefPubMedGoogle Scholar
  • 50 Zerr M, Hechler B, Freund M. , et al. Major contribution of the P2Y1receptor in purinergic regulation of TNFα-induced vascular inflammation. Circulation 2011; 123 (21) 2404-2413
    CrossrefPubMedGoogle Scholar
  • 51 Hechler B, Freund M, Ravanat C, Magnenat S, Cazenave JP, Gachet C. Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors. Circulation 2008; 118 (07) 754-763
    CrossrefPubMedGoogle Scholar
  • 52 Liu R, Ma S, Lu Z, Shen H, Sun L, Wei M. The ADP antagonist MRS2179 regulates the phenotype of smooth muscle cells to limit intimal hyperplasia. Cardiovasc Drugs Ther 2015; 29 (01) 23-29
    CrossrefPubMedGoogle Scholar
  • 53 Marques-da-Silva C, Burnstock G, Ojcius DM, Coutinho-Silva R. Purinergic receptor agonists modulate phagocytosis and clearance of apoptotic cells in macrophages. Immunobiology 2011; 216 (1–2): 1-11
    CrossrefPubMedGoogle Scholar
  • 54 Darbousset R, Delierneux C, Mezouar S. , et al. P2 × 1 expressed on polymorphonuclear neutrophils and platelets is required for thrombosis in mice. Blood 2014; 124 (16) 2575-2585
    PubMedGoogle Scholar
  • 55 Ilkan Z, Watson S, Watson SP, Mahaut-Smith MP. P2 × 1 receptors amplify FcγRIIa-induced Ca2+ increases and functional responses in human platelets. Thromb Haemost 2018; 118 (02) 369-380
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Lecut C, Faccinetto C, Delierneux C. , et al. ATP-gated P2 × 1 ion channels protect against endotoxemia by dampening neutrophil activation. J Thromb Haemost 2012; 10 (03) 453-465
    CrossrefPubMedGoogle Scholar
  • 57 Maître B, Magnenat S, Heim V. , et al. The P2 × 1 receptor is required for neutrophil extravasation during lipopolysaccharide-induced lethal endotoxemia in mice. J Immunol 2015; 194 (02) 739-749
    CrossrefPubMedGoogle Scholar
  • 58 El Mdawar MB, Maître B, Magnenat S, Gachet C, Hechler B, de la Salle H. The ATP-gated P2X1 ion channel contributes to the severity of antibody-mediated transfusion-related acute lung injury in mice. Sci Rep 2019; 9 (01) 5159
    CrossrefPubMedGoogle Scholar
  • 59 Sesma JI, Weitzer CD, Livraghi-Butrico A. , et al. UDP-glucose promotes neutrophil recruitment in the lung. Purinergic Signal 2016; 12 (04) 627-635
    CrossrefPubMedGoogle Scholar
  • 60 Amison RT, Arnold S, O'Shaughnessy BG. , et al. Lipopolysaccharide (LPS) induced pulmonary neutrophil recruitment and platelet activation is mediated via the P2Y1 and P2Y14 receptors in mice. Pulm Pharmacol Ther 2017; 45: 62-68
    CrossrefPubMedGoogle Scholar